Ulta Beauty Shorts Build as Jefferies Lifts Target to $730

Ulta Beauty has spent the past month staging a recovery that has wrong-footed its short sellers, yet bearish positioning has quietly climbed to its highest level in at least a year even as the stock trades 12.7% above where it was a month ago.

Short interest has risen to 5.65% of the free float, up roughly 11% over the past month. That is the most concentrated bearish positioning ORTEX has recorded for the stock in the trailing twelve months. The build has been gradual rather than aggressive: positions drifted higher through October without any single-day spike, and the cost to borrow remains low at 0.51%, barely changed on the week. The lending pool itself is not under any strain. Availability is running near 1,929%, meaning there are almost twenty shares available to borrow for every one already shorted. For context, the tightest this market reached over the past year was around 980%, still well above any threshold that would create squeeze dynamics. Shorts are adding, but the borrow market is giving them no reason to rush for the exit.

Options positioning is the least interesting variable right now. The put/call ratio is 0.89, fractionally below its 20-day average of 0.91, and essentially flat on the z-score basis. Unlike the cautious defensive postures seen in late September, when the PCR ran above 1.0 for several weeks, the options market has rotated toward neutrality as the stock has recovered. That shift mirrors what has happened in the share price: ULTA gained 5.3% on the week, comfortably ahead of the median gain of roughly 1.5% for its closest correlated peers. SBH added 4.5% over the same period, HD rose 3.3%, and FIVE was essentially flat at plus 0.2%.

The most concrete piece of new information this week came from the Street. Jefferies raised its price target on Ulta to $730 from $670 on October 23, maintaining a Buy rating. That target sits well above the consensus mean of $635.84 and roughly 17% above the current price of $624.46. The broader analyst picture is constructive: 14 analysts carry a Buy, and the direction of travel since the August quarterly results has been mostly positive, with Goldman Sachs, DA Davidson and Barclays all lifting targets after the print, even as UBS and Bank of America trimmed slightly. Wells Fargo stepped up its view in mid-September, moving from Underweight to Equal-Weight with a new target of $525. The outliers on valuation are notable too: the forward PE has expanded to 20.2x, up roughly 2.8 turns over the past month, reflecting the share price recovery rather than any change in the earnings base. The EV/EBITDA multiple has moved in the same direction, adding about half a turn over 30 days to sit at 13.8x.

The bull case rests on a comparable sales acceleration. The most recent quarter delivered 5.8% comp growth, well above prior guidance, with e-commerce running at mid-teens in the second half of last year. Bears point to a gross margin that has dipped to 38.1% and an adjusted EPS of $8.01 that missed expectations. They also flag the winding down of the Target partnership and higher operating expenses as drags that complicate the path to earnings recovery. The sector factor score of 86 ranks Ulta near the top of its competitive group, but the short score of 43.8 and an EV/EBIT factor rank of just 35 suggest the market is not yet giving full credit for the recovery narrative.

Retail attention has picked up alongside the share price move. Wikipedia traffic is running 1.8 standard deviations above its own 90-day average, a sign of broader public interest in the name, though the dataset has not been measured as a lead for the company's financial results. The CEO, Kecia Steelman, sold 2,000 shares at roughly $545.88 in mid-September, for proceeds of about $1.09 million. That transaction was not made under a pre-arranged 10b5-1 trading plan, which makes it a more deliberate action, though the sale came when the stock was trading more than 14% below current levels. Net insider activity over the trailing 90 days is a modest net negative of about 2,600 shares sold, largely reflecting that open-market sale. The institutional register is stable: BlackRock holds 9.4% and Vanguard Capital around 7.2%, with neither making material moves in the most recent filing period.

The next quarterly print is scheduled for December 3, forty days away. Between now and then, the question is whether the short interest build at the one-year high holds, fades with the stock, or accelerates toward the print.